An interventional study of Evaluation by magnetic sensor in Lower Extremity Artery Disease, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.
Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 38th largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2024, is one of 43 with no phase, reaches primary completion later than 8 of the 26 other live ones, and was the 109th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18+
Intervascular · Sites in France, United States, Belgium and 1 more country
Ages 18+
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Atrium Medical Corporation · Sites in France, United States
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 13 · Phase 4 7
First in 2002; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 106 across the 66 interventional studies, 298 across the 54 observational. Of the 82 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 120 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
University Hospital, Montpellier has 2 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
| NCT07322913IntervascularIntervascular Post-Market Clinical Follow-Up (PMCF) Registry | 2027-07 |
| NCT07181434Poitiers University HospitalImpact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Peripheral Arterial Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The measurement of magnetic fields emitted by cardiac activity has already been studied in magneto-cardiography. To date, however, this technology has never been evaluated in the peripheral circulation.
The magnetic susceptibility of iron in the circulating blood and the ionic currents in the blood stream generate a very weak induced magnetic current, which can be detected by the micro-sensor of the prototype investigators wish to study.
Proving the validity of this prototype would make it a new diagnostic and even prognostic tool, non-invasive, less costly and more accessible than Doppler for screening peripheral arterial disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The CapMagic device is a small magnetic sensor, whose technology is derived from magnetocardiography, with a very weak field identical to that of a refrigerator magnet, which is placed on the foot or toe to record curves reflecting the state of the arterial network. It does not require direct skin contact.
Device: Evaluation by magnetic sensor
Evaluation by magnetic sensor on arm and leg
Correlation of the two curve amplitudes (y) versus time (x) between the signal recording obtained by the CapMagic prototype on the radial artery and the pulsed echo-Doppler recording on the radial artery
Correlation of the two curve amplitudes (y) versus time (x) between the signal recording obtained by the CapMagic prototype on the radial artery and the pulsed echo-Doppler recording on the radial artery, in adult patients with or without AOMI in hospital. The result is expressed by a Spearman correlation coefficient ranging from -1 to 1, with 0 corresponding to no correlation and 1 corresponding to a perfect positive correlation
Time frame: On day 1
Correlations of the two curve amplitudes (y) versus time (x) between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording, measured on the plantar artery on one side and on the pulpal artery on the other
Correlations of the two curve amplitudes (y) versus time (x) between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording, measured on the plantar artery on one side and on the pulpal artery on the other, in adult patients with or without LEAD in hospital. The result is expressed by a Spearman correlation coefficient ranging from -1 to 1, with 0 corresponding to no correlation and 1 corresponding to a perfect positive correlation
Time frame: On day 1
Correlation of the Pulsatility index (or Gosling Pulsatility index) between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording
IP=P/M where P=maximum amplitude of the trace (from highest positive value, i.e. peak systolic, to lowest value) and M=average circulatory velocity, averaged over the entire cardiac cycle. Calculated from the Doppler or CapMagic curves.
Time frame: On day 1
Correlation of the Systolic rise time (SRT) between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording
Systolic rise time (SRT), (ms) : the time between the foot and the peak of the pulse wave. Calculated from the Doppler or CapMagic curves.
Time frame: On day 1
Correlation of the Systolic peak between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording
Systolic peak, Measured in cm/s or mV: Peak height in systole. Calculated from the Doppler or CapMagic curves.
Time frame: On day 1
Correlation of the maximum acceleration of systolic rise between the signal recording obtained by the CapMagic prototype and the pulsed echo-Doppler recording
The maximum acceleration of systolic rise (cm/s2) calculated from the Doppler or CapMagic curves.
Time frame: On day 1
Correlation of Presence of critical ischemia measured by the CapMagic prototype and the pulsed echo-Doppler recording
critical ischemia is defined by systolic pressure at toe \< 30 mmHg or ankle \< 50mmHg, or diagnosis of critical ischemia retained by the team in the impossibility of obtaining pressure measurements
Time frame: On day 1
Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.
Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 18 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →